Form 8-K - Current report:
SEC Accession No. 0001104659-25-060092
Filing Date
2025-06-17
Accepted
2025-06-17 08:00:41
Documents
14
Period of Report
2025-06-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2518163d1_8k.htm   iXBRL 8-K 25296
2 EXHIBIT 99.1 tm2518163d1_ex99-1.htm EX-99.1 13094
6 GRAPHIC tm2518163d1_ex99-1img001.jpg GRAPHIC 4745
  Complete submission text file 0001104659-25-060092.txt   217608

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mrkr-20250616.xsd EX-101.SCH 3017
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrkr-20250616_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrkr-20250616_pre.xml EX-101.PRE 22360
16 EXTRACTED XBRL INSTANCE DOCUMENT tm2518163d1_8k_htm.xml XML 3808
Mailing Address 2450 HOLCOMBE BLVD SUITE BCM-A, MS: BCM251 HOUSTON TX 77021
Business Address 2450 HOLCOMBE BLVD SUITE BCM-A, MS: BCM251 HOUSTON TX 77021 (713) 400-6400
Marker Therapeutics, Inc. (Filer) CIK: 0001094038 (see all company filings)

EIN.: 880277072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37939 | Film No.: 251051854
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)